Paris (AFP)

The Paris Bourse hesitated (-0.19%) in mid-session Wednesday, worried about potential health restrictions a few hours from a speech by President Emmanuel Macron, at the end of a month of March up by more than 6 %.

The flagship Parisian CAC 40 index lost 11.63 points to 6,076.41 points around 1:00 p.m. (11:00 GMT), in the wake of a decline in Wall Street the day before against a backdrop of tensions on sovereign yields.

"The pandemic continues to arouse fear in Europe, especially in countries most behind in vaccination such as France," says Franklin Pichard, CEO of Kiplink Finance.

The main weapon against the virus, vaccination is struggling to take off while more than 565 million doses have been administered worldwide, according to a count made by AFP from official sources Tuesday at 11:00 GMT.

President Emmanuel Macron will address the French at 8 p.m. Wednesday, which will follow a defense advice Wednesday morning.

Despite these fears, the flagship Paris index should end the month of March with an increase of more than 6%, after an increase of 5.6% in February, helped in particular by the adoption in the United States of a recovery plan $ 1.9 trillion and hopes for economies to normalize after the pandemic.

Voltalia withdraws from Burma

The French producer of renewable energies (-0.86% to 23.05 euros) will "put an end to its activities" in Burma, where the repression of the protest by the military junta in power has killed more than 520 people since February 1, according to a statement released Wednesday.

Capgemini limits breakage

The French IT giant (+ 1.21% to 146.75 euros) limited the impact of the health crisis in 2020, recording a decline in its turnover of 3.2% at constant scope and exchange rates and net profit up 12% to 957 million euros.

Anticancer approved for Ipsen

The laboratory (+ 4.86% to 73.40 euros) announced Wednesday that the European Commission had approved its anticancer treatment Cabometyx, in combination with another Bristol-Myers Squibb molecule, for patients with kidney carcinoma advanced.

© 2021 AFP